GxP compliance software pricing: what a validated eQMS costs, and what Part 11 validation adds on top

The short answer: validated GxP compliance software costs far more than a general compliance platform. Recorded contract data checked on 24 August 2026 puts the median annual spend at $43,989 for Greenlight Guru, $115,673 for MasterControl and $188,460 for Veeva, against a median nearer $20,000 to $25,000 for a general GRC tool like Vanta or Drata. Then add validation effort, which commonly runs 30 to 100 percent of first-year license. None of these vendors publishes a price.

The gap is not vendor greed and it is not feature count. It is that a life sciences platform ships validation documentation, holds a controlled change process you are entitled to audit, and carries the liability of being the system of record for something an FDA investigator will read. That is a different product from a SOC 2 evidence collector, and it is priced like one.

How much does GxP compliance software cost?

Every serious life sciences quality platform is quote-driven, so the only honest pricing data is what buyers actually signed. The table below is Vendr marketplace contract data, pulled 24 August 2026.

Two things stand out. The first is the spread inside Veeva's range: $90,720 at the bottom and $491,710 at the top is more than a five-fold difference for the same vendor, which tells you the quote is driven by scope rather than by a list price you can negotiate against. The second is MasterControl's unusually tight range. A median of $115,673 against a top recorded figure of $116,837 suggests most buyers land in a narrow band, so there is likely less room to move than the Veeva numbers imply.

Do any GxP software vendors publish pricing?

No. On 24 August 2026 we opened the public pricing pages of Greenlight Guru, MasterControl and Qualio directly. All three describe plans or solution tiers. None of the three shows a dollar figure. Greenlight Guru routes to "Talk to Sales", MasterControl asks you to "Get Your Pricing" by phone or form, and Qualio names three tiers, Foundation, Growth and Scale, then says "Request Pricing" and adds that an implementation fee applies to all plans.

That last detail is the useful one, because it is the only place in this market where a vendor states plainly on its own site that implementation is a separate, universal charge. Treat it as the norm rather than the exception. If a quote arrives with no implementation line, that does not mean it is free, it means it has not been scoped yet.

Why does life sciences software cost more than general compliance software?

A general compliance platform sells you evidence collection against a framework. A GxP platform sells you a system of record that has to survive an inspection, and four things drive the difference in price.

• Validation documentation. The vendor produces and maintains qualification material you can leverage, which is engineering and quality effort baked into the license.
• Change control on the vendor side. You are buying the right to be told what changed and to assess it, which constrains how fast the vendor can ship and therefore what it must charge.
• Record retention horizons. Device and drug records outlive most SaaS contracts, so the platform has to guarantee retrieval over periods measured in decades, not renewal cycles.
• Narrower market. There are far fewer FDA-regulated manufacturers than there are companies chasing SOC 2, so fixed costs spread across fewer customers.

None of that makes the premium automatically worth paying. It makes it explicable, which is a better starting point for a negotiation than assuming you are being overcharged.

What does Part 11 validation add on top of the license?

Validation is the line that surprises finance. Budget 30 to 100 percent of first-year license for the first year of a validated implementation, at the top of that band when you are moving records out of a legacy system or running several GxP disciplines on one platform.

The work itself is yours, not the vendor's, and that is a regulatory fact rather than a commercial one. There is no FDA-certified Part 11 software, so no purchase transfers the obligation. A vendor supplies capability and evidence; you supply intended use, configuration, testing of the high-risk functions, procedures, training records and periodic review. Our guide to 21 CFR Part 11 compliant software maps each control in section 11.10 to the thing to make a vendor demonstrate rather than describe, which is the cheapest way to avoid discovering a gap during validation.

One change worth pricing in this year: FDA finalized its Computer Software Assurance guidance on 24 September 2025, at 90 FR 45945, three years after the draft. It endorses a risk-based approach that can lean on unscripted testing, continuous monitoring and supplier evidence instead of scripting every test case. Teams that still budget for exhaustive scripted testing across every function are budgeting against guidance FDA has now superseded, and that is usually worth real money on a large rollout.

What drives the quote

In roughly the order they move the number:

• Modules. Document control, training, CAPA, complaints, supplier quality and audit management are usually priced separately. This is the biggest lever by a distance.
• Sites and legal entities. Multi-site manufacturers pay per site far more often than per seat, and a second manufacturing site can cost more than doubling headcount.
• Named users versus read-only. Most vendors distinguish the two. Get the split right before the quote, because reclassifying users later is a renewal conversation.
• Validation package tier. Several vendors sell basic qualification material with the license and charge for the fuller package.
• Storage and retention. Usually negligible in GRC, occasionally not here, because imaging and batch records are large and retention is long.

What to ask before you sign

Five questions that change the number or the risk, and that most buyers skip:

• What exactly is in the validation package, and what does it explicitly leave to us?
• How are we notified of a release, how long do we get to assess it, and can we defer one?
• What does data export look like at the end of the contract, in human readable and electronic form, including audit trails?
• Which predicate rule does each record type in the product answer to?
• What is the implementation fee, and what happens to it if scope grows mid-project?

The export question is the one people regret. A validated system holds records you are obliged to retrieve for years after you stop paying for the software, and the time to establish how that works is before signature, not during a migration. It is closely related to a discipline worth building anyway: knowing when the data feeding your quality records goes stale, changes shape or stops arriving, which is what continuous monitoring of data freshness and anomalies is for, and which quietly underpins any data integrity claim you make to an inspector.

Is a general GRC platform ever enough?

Sometimes, and it is worth asking honestly. If your regulated records live in a validated system you already own, and what you need is obligation tracking, policy attestation and audit readiness across several frameworks, a general platform at a fifth of the price may be the right answer. The per-vendor medians and negotiation spreads for general compliance platforms are worth comparing before you assume the life sciences premium is unavoidable.

Where it stops being enough is the moment the platform itself becomes the system of record for a record a predicate rule requires. At that point it inherits every obligation in 21 CFR Part 11, including validation, audit trails and signature controls, and a tool that was never built for it will fail on the least glamorous requirement in the regulation: producing an accurate and complete copy of a record, with its audit trail, in a form an investigator can read.